Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated July 18, 2022, announces the completion of the GSK Share Consolidation. This corporate action follows the shareholder approval granted on July 6, 2022, and the recent demerger of the Consumer Healthcare business to form Haleon. The consolidation became effective at 8:00 a.m. UK time on July 19, 2022.
Key Financial Metrics and Capital Structure
The filing focuses on capital structure adjustments rather than operational financial performance. Key metrics include:
- Consolidation Ratio: 4 new ordinary shares for every 5 existing ordinary shares.
- Post-Consolidation Share Capital: 4,311,276,836 ordinary shares of 31¼ pence each (including 243,924,760 shares held in treasury).
- Total Voting Rights: 4,067,352,076 as of July 19, 2022.
- Dividend Adjustments: To maintain aggregate payout in absolute terms, expected dividends were adjusted to 16.25p per new share for Q2 2022, 27.5p for H2 2022, and 56.25p for 2023.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes Versus Prior Period
The primary material change is the reduction in the number of outstanding shares and the corresponding increase in share price due to the 4-for-5 consolidation. Additionally, the company's share capital structure has been altered following the demerger of Haleon. American Depositary Shares (ADS) will also be consolidated on a 4-for-5 basis, with new ADSs trading under CUSIP 37733W204.
Guidance, Outlook, and Risks
Outlook and Timetable:
- New ordinary shares began trading on the London Stock Exchange on July 19, 2022.
- New ADSs commenced "when-issued" trading on the NYSE on July 19, 2022, with regular trading starting July 22, 2022.
- Q2 2022 results, which will confirm the Q2 dividend, are expected to be published on July 27, 2022.
Risks and Contingencies:
- Fractional entitlements arising from the consolidation will be aggregated and sold in the open market, with net proceeds paid to shareholders.
- Forward-looking statements are subject to risks including those described in the 2021 Form 20-F, Q1 2022 results, and impacts of the COVID-19 pandemic.
Important Facts for Investor Verification
- Verify the effective date of the share consolidation (July 19, 2022) and the new ISIN (GB00BN7SWP63) and CUSIP (37733W204) for trading purposes.
- Confirm the adjusted dividend per share amounts (16.25p for Q2, 27.5p for H2, 56.25p for 2023) to ensure portfolio yield calculations are accurate.
- Check the total number of voting rights (4,067,352,076) for compliance with disclosure thresholds under FCA rules.
- Monitor the July 27, 2022 earnings release for the official declaration of the Q2 2022 dividend.